Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05148871
PHASE2/PHASE3

Australian Phase 2b Study to Assess Effect of Dose Interval on Spikogen Covid-19 Vaccine

Sponsor: Vaxine Pty Ltd

View on ClinicalTrials.gov

Summary

A study to assess the effect of varying the time interval between doses on the immunogenicity of an adjuvanted recombinant spike protein Covid-19 vaccine (Spikogen/Covax-19)

Official title: A Phase 2b Study to Assess the Effect of Dose Interval on the Effectiveness of a Protein-based Covid-19 Vaccine (Spikogen® Vaccine)

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

200

Start Date

2022-03-01

Completion Date

2024-10-06

Last Updated

2024-08-07

Healthy Volunteers

Yes

Conditions

Interventions

BIOLOGICAL

Spikogen/Covax-19

Spikogen/Covax-19 is a recombinant spike protein vaccine formulated with Advax-CpG55.2 adjuvant

Locations (1)

ARASMI

Adelaide, South Australia, Australia